Glimestar-M 3 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The prolonged-release formulation of Glimestar-M 3 ensures a sustained therapeutic effect, promoting better patient compliance through once-daily dosing. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. It is essential to monitor blood glucose regularly and adjust the dosage based on individual response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to glimepiride. Glimestar-M 3 should be used under strict medical supervision with appropriate lifestyle modifications to optimize therapeutic outcomes in type 2 diabetes management.